222 related articles for article (PubMed ID: 32162442)
1. Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features.
Jiang Y; Guo X; Liu L; Rode S; Wang R; Liu H; Yang ZQ
Cancer Sci; 2020 May; 111(5):1829-1839. PubMed ID: 32162442
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Lysine Acetyltransferase Activity of Recombinant Human ARD1/NAA10.
Vo TTL; Park JH; Lee EJ; Nguyen YTK; Han BW; Nguyen HTT; Mun KC; Ha E; Kwon TK; Kim KW; Jeong CH; Seo JH
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013195
[TBL] [Abstract][Full Text] [Related]
3. Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy.
White J; Derheimer FA; Jensen-Pergakes K; O'Connell S; Sharma S; Spiegel N; Paul TA
Trends Pharmacol Sci; 2024 Mar; 45(3):243-254. PubMed ID: 38383216
[TBL] [Abstract][Full Text] [Related]
4. N-α-acetyltransferase 10 (NAA10) in development: the role of NAA10.
Lee MN; Kweon HY; Oh GT
Exp Mol Med; 2018 Jul; 50(7):1-11. PubMed ID: 30054454
[TBL] [Abstract][Full Text] [Related]
5. Versatility of ARD1/NAA10-mediated protein lysine acetylation.
Vo TTL; Jeong CH; Lee S; Kim KW; Ha E; Seo JH
Exp Mol Med; 2018 Jul; 50(7):1-13. PubMed ID: 30054464
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylation of the Acetyltransferase NAA10 Trp38 Is Not an Enzyme-Switch in Human Cells.
Ree R; Krogstad K; McTiernan N; Jakobsson ME; Arnesen T
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769235
[TBL] [Abstract][Full Text] [Related]
7. NAA10 as a New Prognostic Marker for Cancer Progression.
Kim SM; Ha E; Kim J; Cho C; Shin SJ; Seo JH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126484
[TBL] [Abstract][Full Text] [Related]
8. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10.
Yang H; Li Q; Niu J; Li B; Jiang D; Wan Z; Yang Q; Jiang F; Wei P; Bai S
Oncotarget; 2016 Jan; 7(3):2709-20. PubMed ID: 26646451
[TBL] [Abstract][Full Text] [Related]
9. A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly.
Ree R; Geithus AS; Tørring PM; Sørensen KP; Damkjær M; ; Lynch SA; Arnesen T
BMC Med Genet; 2019 Jun; 20(1):101. PubMed ID: 31174490
[TBL] [Abstract][Full Text] [Related]
10. Genome-scale analysis of regulatory protein acetylation enzymes from photosynthetic eukaryotes.
Uhrig RG; Schläpfer P; Mehta D; Hirsch-Hoffmann M; Gruissem W
BMC Genomics; 2017 Jul; 18(1):514. PubMed ID: 28679357
[TBL] [Abstract][Full Text] [Related]
11. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
Attar N; Kurdistani SK
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27881443
[TBL] [Abstract][Full Text] [Related]
12.
McTiernan N; Darbakk C; Ree R; Arnesen T
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255974
[TBL] [Abstract][Full Text] [Related]
13. Histone Lysine and Genomic Targets of Histone Acetyltransferases in Mammals.
Voss AK; Thomas T
Bioessays; 2018 Oct; 40(10):e1800078. PubMed ID: 30144132
[TBL] [Abstract][Full Text] [Related]
14. A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy.
Støve SI; Blenski M; Stray-Pedersen A; Wierenga KJ; Jhangiani SN; Akdemir ZC; Crawford D; McTiernan N; Myklebust LM; Purcarin G; McNall-Knapp R; Wadley A; Belmont JW; Kim JJ; Lupski JR; Arnesen T
Eur J Hum Genet; 2018 Sep; 26(9):1294-1305. PubMed ID: 29748569
[TBL] [Abstract][Full Text] [Related]
15. Diverse roles of arrest defective 1 in cancer development.
Chaudhary P; Ha E; Vo TTL; Seo JH
Arch Pharm Res; 2019 Dec; 42(12):1040-1051. PubMed ID: 31813105
[TBL] [Abstract][Full Text] [Related]
16. Microfluidic Mobility Shift Profiling of Lysine Acetyltransferases Enables Screening and Mechanistic Analysis of Cellular Acetylation Inhibitors.
Sorum AW; Shrimp JH; Roberts AM; Montgomery DC; Tiwari NK; Lal-Nag M; Simeonov A; Jadhav A; Meier JL
ACS Chem Biol; 2016 Mar; 11(3):734-41. PubMed ID: 26428393
[TBL] [Abstract][Full Text] [Related]
17. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal Acetyltransferase Naa10/ARD1 Does Not Acetylate Lysine Residues.
Magin RS; March ZM; Marmorstein R
J Biol Chem; 2016 Mar; 291(10):5270-7. PubMed ID: 26755727
[TBL] [Abstract][Full Text] [Related]
19.
Kweon HY; Lee MN; Dorfel M; Seo S; Gottlieb L; PaPazyan T; McTiernan N; Ree R; Bolton D; Garcia A; Flory M; Crain J; Sebold A; Lyons S; Ismail A; Marchi E; Sonn SK; Jeong SJ; Jeon S; Ju S; Conway SJ; Kim T; Kim HS; Lee C; Roh TY; Arnesen T; Marmorstein R; Oh GT; Lyon GJ
Elife; 2021 Aug; 10():. PubMed ID: 34355692
[TBL] [Abstract][Full Text] [Related]
20. KATs off: Biomedical insights from lysine acetyltransferase inhibitors.
Whedon SD; Cole PA
Curr Opin Chem Biol; 2023 Feb; 72():102255. PubMed ID: 36584580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
